WINTON GROUP Ltd Invests $220,000 in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

WINTON GROUP Ltd acquired a new position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 18,467 shares of the company’s stock, valued at approximately $220,000.

Separately, Rhumbline Advisers purchased a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $123,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Stock Down 1.2 %

GYRE stock opened at $13.87 on Thursday. Gyre Therapeutics, Inc. has a one year low of $4.80 and a one year high of $30.40. The company has a 50 day moving average price of $12.95 and a two-hundred day moving average price of $13.95.

Gyre Therapeutics (NASDAQ:GYRE) last released its earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The firm had revenue of $25.23 million during the quarter. On average, sell-side analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Gyre Therapeutics

In other Gyre Therapeutics news, Director Nassim Usman sold 3,452 shares of Gyre Therapeutics stock in a transaction on Friday, June 28th. The shares were sold at an average price of $12.00, for a total value of $41,424.00. Following the transaction, the director now owns 1,636 shares in the company, valued at approximately $19,632. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.92% of the stock is owned by company insiders.

Gyre Therapeutics Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.